初次全髋关节置换术中关节腔内万古霉素粉末使用的前瞻性质量控制研究
该研究基于前瞻性质量控制项目进行回顾性分析,比较初次全髋关节置换术中关节腔内使用万古霉素粉末(IVP)与不使用者的结局。共分析1193例患者,IVP组523例(43.8%),非IVP组670例(56.2%)。结果显示IVP组培养阳性关节感染率、再手术率、伤口并发症再手术率及再入院率均高于非IVP组,作者主张在进一步随机研究明确前不使用IVP。
要点
- IVP组培养阳性关节感染率为1.7%[0.8,3.2],高于非IVP组的0.3%[0.04,1.1](P=.01)。
- IVP组总体再手术率为6.1%[4.2,8.5],高于非IVP组的2.4%[1.4,3.9](P<.01)。
- IVP组因伤口并发症再手术率为2.7%[1.5,4.5],高于非IVP组的0.7%[0.2,1.7](P<.01)。
核心结论
- 在初次全髋关节置换术中,使用关节腔内万古霉素粉末与更高的假体周围关节感染率、总体再手术率、因伤口并发症再手术率及再入院率相关。
- 在未来的前瞻性随机研究明确关节腔内万古霉素粉末在全髋关节置换术中的安全性和有效性之前,作者主张不使用该干预。
研究设计与样本
- 研究为前瞻性质量控制项目的回顾性分析,纳入2021年10月至2022年9月期间10名高手术量全髋关节置换术外科医生每月交替使用或不使用关节腔内万古霉素粉末,其他围手术期方案保持不变。
- 共分析1193例初次全髋关节置换术患者,其中523例(43.8%)接受关节腔内万古霉素粉末纳入IVP组,670例(56.2%)未接受纳入非IVP组。
- 主要结局为初次全髋关节置换术后90天内培养阳性感染,次要结局包括革兰阳性培养、总体再手术率、伤口并发症、再入院及术后90天内伤口并发症。
- 两组年龄、体重指数和性别相似(P>.25)。
主要发现
- IVP组培养阳性关节感染率为1.7%[0.8,3.2],非IVP组为0.3%[0.04,1.1],IVP组更高(P=.01)。
- 两组所有假体周围关节感染均为革兰阳性细菌。
- IVP组总体再手术率为6.1%[4.2,8.5],非IVP组为2.4%[1.4,3.9],IVP组更高(P<.01)。
- IVP组因任何伤口并发症再手术率为2.7%[1.5,4.5],非IVP组为0.7%[0.2,1.7],IVP组更高(P<.01)。
- IVP组总体再入院率为6.1%[4.2,8.5],非IVP组为2.8%[1.7,4.4],IVP组更高(P<.01);IVP组疑似感染再入院率为2.1%[1.1,3.7],非IVP组为0.6%[0.02,1.5],IVP组更高(P=.03)。
临床怎么用
- 作者主张在未来的前瞻性随机研究明确关节腔内万古霉素粉末在全髋关节置换术中的安全性和有效性之前,不使用该干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this retrospective analysis of a prospective quality control project was to determine whether the use of intrawound vancomycin powder (IVP) decreases the rate of periprosthetic joint infection (PJI) within 90 days following primary total hip arthroplasty (THA). METHODS: From October 2021 to September 2022, a prospective quality control project was undertaken in which 10 high-volume THA surgeons alternated between using and not using IVP each month while keeping other perioperative protocols unchanged. A retrospective analysis of the project was performed to compare the group of patients who received IVP to the group of patients who did not. The primary outcome was a culture positive infection within 90 days following primary THA. Secondary outcomes included gram-positive culture, overall reoperation rate, wound complications, readmission, and wound complications within 90 days post-operatively. A total of 1,193 primary THA patients were identified for analysis. There were 523 (43.8%) patients who received IVP and were included in the IVP group, while 670 (56.2%) did not and were included in the non-IVP group. Age, body mass index, and sex were similar between the 2 groups (P > .25). RESULTS: The IVP group had a higher rate of culture positive joint infections (1.7 [0.8, 3.2] versus 0.3% [0.04, 1.1], P = .01) than the non-IVP group. All PJI's were found to have gram positive bacteria in both groups. The IVP group had a higher overall reoperation rate than the non-IVP group (6.1 [4.2, 8.5] versus 2.4% [1.4, 3.9], P < .01). The IVP group had a higher reoperation rate for any wound complication compared to non-IVP patients (2.7 [1.5, 4.5] versus 0.7% [0.2, 1.7], P < .01). The overall readmission rate (6.1 [4.2, 8.5] versus 2.8% [1.7, 4.4], P < .01), as well as readmission for suspected infection (2.1 [1.1, 3.7] versus 0.6% [0.02, 1.5], P = .03), were higher in the IVP group. CONCLUSIONS: The use of IVP in primary THA was associated with a higher rate of PJI, overall reoperation, reoperation for wound complications, and readmission in a prospective quality control project. Until future prospective randomized studies determine the safety and efficacy of IVP in THA conclusively, we advocate against its utilization.
引用
- Doxey SA, Urdahl TH, Solaiman RH, et al. Intrawound Vancomycin Powder in Primary Total Hip Arthroplasty: A Prospective Quality Control Study. J Arthroplasty. 2024. PMID: 38599528. doi:10.1016/j.arth.2024.03.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。